Interchangeability may be where FDA can leave its regulatory mark in the biosimilar arena because European rules have not yet addressed it.
FDA’s three biosimilar guidances were largely silent on interchangeability and the agency has asked for additional comments on this and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?